3 results
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
The study is intended to provide insight into the clinical feasibility of the Exilis* system as a therapy for obesity, including:* Providing initial human safety data on the Exilis* system, * Gaining an understanding of how to individually titrate…
In this study, we want to combine rTMS and CCT to assess whether the combination of these two treatment would have synergistic effects and strengthen each other. We specifically want to assess the effect on mood and cognitive control, in a group of…